Skip to content

To investigate the serum cholinesterase levels in patients with severe community-acquired pneumonia, and explore its clinical role and significance.

The Clinical Value of Serum Cholinesterase in Patients with Severe Community-Acquired Pneumonia: An Observational Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600126513
Enrollment
Unknown
Registered
2026-06-10
Start date
2026-06-15
Completion date
Unknown
Last updated
2026-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe Community-Acquired Pneumonia (SCAP)

Interventions

Survival group vs. Non-survival group:None

Sponsors

The Affiliated Hospital of Xuzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria for community-acquired pneumonia (CAP), and are diagnosed as severe community-acquired pneumonia according to relevant guidelines. 2. Aged >= 18 years. 3. Serum cholinesterase test completed at admission, with complete clinical and laboratory data.

Exclusion criteria

Exclusion criteria: 1. Complicated with severe liver failure, liver cirrhosis, active liver disease or other liver diseases that can significantly affect cholinesterase synthesis. 2. Complicated with severe non-infectious severe stress states such as severe malnutrition, cachexia, severe burns or major trauma. 3. Have used organophosphorus pesticides, cholinesterase inhibitors or other drugs that can significantly affect serum cholinesterase activity within the past 3 months. 4. Hospital-acquired pneumonia, immunosuppression-related pneumonia, pulmonary tuberculosis, pulmonary fungal diseases and other atypical pulmonary infections. 5. Complicated with severe cardiac, renal, nervous system diseases or advanced malignant tumors, with an expected survival time < 28 days. 6. Pregnant or lactating women. 7. Loss to follow-up, or inability to cooperate with the study.

Design outcomes

Primary

MeasureTime frame
28-day all-cause mortality rate;Area under the ROC curve, sensitivity, specificity, positive predictive value, negative predictive value;

Secondary

MeasureTime frame
Mortality rate during hospitalization;Correlation coefficient between ChE score and outcome;Occurrence of severe complications (such as infection, bleeding, etc.);

Countries

China

Contacts

Public ContactZhang Wenhui

The Affiliated Hospital of Xuzhou Medical University

xzzyz2000@126.com+86 516 85806235

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 21, 2026